France
ENCEFA, founded in 2016 and headquartered in France, is a biotechnology company pioneering cell rejuvenation therapies for age-related diseases. Their innovative approach involves developing novel CD38 modulators that enhance cellular autophagy and energy metabolism, addressing cellular senescence—a key component in aging.
Their recent work has led to the discovery of a biological pathway where CD38 is utilized in a unique way, a breakthrough protected by three patents. This method resembles a natural rescue mechanism impaired during aging, leading to increased NAD+ levels and improved cellular function. Their flagship product, NC-B8, is a revolutionary brain-penetrant antibody aimed at neurodegenerative conditions like Amyotrophic Lateral Sclerosis (ALS). Concurrently, NC-P7 is designed to protect vital organs, such as the heart and kidneys, against age-related metabolic issues.
As demonstrated in preclinical trials involving mice, rats, and dogs, ENCEFA's products show promise in rejuvenating organs and minimizing inflammation in pathological contexts. Their last investment was a $250,000 Seed Round on 30 December 2021, led by Newchip Accelerator, highlighting investor interest in their potential to transform longevity treatment.
